Met Life Investment Management, LLC Fennec Pharmaceuticals Inc. Transaction History
Met Life Investment Management, LLC
- $20.1 Billion
- Q3 2025
A detailed history of Met Life Investment Management, LLC transactions in Fennec Pharmaceuticals Inc. stock. As of the latest transaction made, Met Life Investment Management, LLC holds 9,593 shares of FENC stock, worth $77,703. This represents 0.0% of its overall portfolio holdings.
Number of Shares
9,593
Previous 15,208
36.92%
Holding current value
$77,703
Previous $126,000
30.16%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding FENC
# of Institutions
87Shares Held
14.2MCall Options Held
10KPut Options Held
83.8K-
Southpoint Capital Advisors LP New York, NY4.08MShares$33 Million1.08% of portfolio
-
Sonic Gp LLC Honolulu, HI2.41MShares$19.5 Million33.54% of portfolio
-
Solas Capital Management, LLC Darien, CT2.19MShares$17.7 Million14.46% of portfolio
-
Black Rock Inc. New York, NY1.19MShares$9.62 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA956KShares$7.74 Million0.0% of portfolio
About FENNEC PHARMACEUTICALS INC.
- Ticker FENC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,067,300
- Market Cap $211M
- Description
- Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec...